Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models

BACKGROUND: Bevacizumab is being incorporated as first-line therapy with standard-of-care chemotherapy on epithelial ovarian carcinoma (EOC). We investigated bevacizumab combined with chemotherapy on tumour progression and mouse survival in EOC xenograft models. METHODS: Bevacizumab was administered...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Oliva, P, Decio, A, Castiglioni, V, Bassi, A, Pesenti, E, Cesca, M, Scanziani, E, Belotti, D, Giavazzi, R
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2012
Assuntos:
Molecular Diagnostics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3394985/
https://ncbi.nlm.nih.gov/pubmed/22713663
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.261
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados